Abstract:Background: The prevalence of depression has been increasing worldwide in recent years, posing a heavy burden on patients and society. However, the diagnostic and therapeutic tools available for this disease are inadequate. Therefore, this research focused on the identification of potential biomarkers in the peripheral blood of patients with depression. Methods: The expression dataset GSE98793 of depression was provided by the Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/gds). Initially, differentially expressed genes (DEGs) were detected in GSE98793. Subsequently, the most relevant modules for depression were screened according to weighted gene co-expression network analysis (WGCNA). Finally, the identified DEGs were mapped to the WGCNA module genes to obtain the intersection genes. In addition, Gene Ontology (GO), Disease Ontology (DO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were conducted on these genes. Moreover, biomarker screening was carried out by protein-protein interaction (PPI) network construction of intersection genes on the basis of various machine learning algorithms. Furthermore, the gene set enrichment analysis (GSEA), immune function analysis, transcription factor (TF) analysis, and the prediction of the regulatory mechanism were collectively performed on the identified biomarkers. In addition, we also estimated the clinical diagnostic ability of the obtained biomarkers, and performed Mfuzz expression pattern clustering and functional enrichment of the most potential biomarkers to explore their regulatory mechanisms. Finally, we also perform biomarker-related drug prediction. Results: Differential analysis was used for obtaining a total of 550 DEGs and WGCNA for obtaining 1,194 significant genes. Intersection analysis of the two yielded 140 intersection genes. Biological functional analysis indicated that these genes had a major role in inflammation-related bacterial infection pathways and cardiovascular diseases such as atherosclerosis. Subsequently, the genes S100A12, SERPINB2, TIGIT, GRB10, and LHFPL2 in peripheral serum were identified as depression biomarkers by using machine learning algorithms. Among them, S100A12 is the most valuable biomarker for clinical diagnosis. Finally, antidepressants, including disodium selenite and eplerenone, were predicted. Conclusion: The genes S100A12, TIGIT, SERPINB2, GRB10, and LHFPL2 in peripheral serum are viable diagnostic biomarkers for depression. and contribute to the diagnosis and prevention of depression in clinical practice.

Identification of Diagnostic Markers for Major Depressive Disorder Using Machine Learning Methods

Identification of Diagnostic Markers for Major Depressive Disorder by Cross-Validation of Data from Whole Blood Samples.

Identification of Potential Biomarkers for Major Depressive Disorder: Based on Integrated Bioinformatics and Clinical Validation

Integrated Analysis of Methylomic and Transcriptomic Data to Identify Potential Diagnostic Biomarkers for Major Depressive Disorder

Peripheral Blood Mononuclear Cell Biomarkers for Major Depressive Disorder: A Transcriptomic Approach

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Identifying patients with major depressive disorder based on tryptophan hydroxylase-2 methylation using machine learning algorithms

A Machine Learning Analysis of Big Metabolomics Data for Classifying Depression: Model Development and Validation

A diagnostic model based on bioinformatics and machine learning to differentiate bipolar disorder from schizophrenia and major depressive disorder

Using an Interpretable Amino Acid-Based Machine Learning Method to Enhance the Diagnosis of Major Depressive Disorder

An integrated machine learning framework for developing and validating a diagnostic model of major depressive disorder based on interstitial cystitis-related genes

MicroRNA classification and discovery for major depressive disorder diagnosis: Towards a robust and interpretable machine learning approach

Machine learning in major depression: From classification to treatment outcome prediction

Sleep Disturbance-Related Neuroimaging Features As Potential Biomarkers for the Diagnosis of Major Depressive Disorder: A Multicenter Study Based on Machine Learning

Diagnosis of Major Depressive Disorder Using Machine Learning Based on Multisequence MRI Neuroimaging Features

Development of Machine-Learning-driven Signatures for Diagnosing and Monitoring Therapeutic Response in Major Depressive Disorder Using Integrated Immune Cell Profiles and Plasma Cytokines

Identification of mitophagy-related genes and analysis of immune infiltration in the astrocytes based on machine learning in the pathogenesis of major depressive disorder

Construction and Analysis of a Diagnostic Model Based on Differential Expression Genes in Patients With Major Depressive Disorder

Screening of potential biomarkers in peripheral blood of patients with depression based on weighted gene co-expression network analysis and machine learning algorithms

A Systematic Evaluation of Machine Learning–Based Biomarkers for Major Depressive Disorder

BLOOD-BASED GENE EXPRESSION PROFILES FOR CLASSIFICATION OF SUBSYNDROMAL SYMPTOMATIC DEPRESSION AND MAJOR DEPRESSIVE DISORDER